Phase I Clinical Trial of Vorinostat (MK0683) in Combination With Bortezomib in Patients With Advanced Multiple Myeloma

Trial Profile

Phase I Clinical Trial of Vorinostat (MK0683) in Combination With Bortezomib in Patients With Advanced Multiple Myeloma

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2015

At a glance

  • Drugs Vorinostat (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Merck & Co
  • Most Recent Events

    • 21 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 21 Jun 2011 Status changed from active, no longer recruiting to completed reported by ClinicalTrials.gov.
    • 17 Dec 2010 Official Title amended as reported by ClinicalTrials.gov (NCT00111813).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top